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background: Soluble ST2 (sST2), a member of the interleukin-1 receptor family, is a sensitive marker of cardiac stress, but is not cardiac specific. 
Prior studies have evaluated sST2 in low- to intermediate- risk asymptomatic individuals, but whether these findings would translate to community 
dwelling older adults is uncertain.
objectives: To determine if sST2 is predictive of incident heart failure (HF) or cardiovascular death (CV) in an older patient population with no 
previous history of HF.
Methods: Using the Cardiovascular Health Study, a cohort of community dwelling adults ≥ 65 years; sST2 was measured using the Presage assay in 
3915 participants without HF. Participants were followed-up for a median of 13.6 years (interquartile range 8.2, 18.2) for incident HF and CV death. 
sST2 was analyzed across quintiles, as a continuous variable (log transformed) and at its approved cut-off of 35 ng/mL.
results: There were 1185 HF and 1026 CV death events in the study population who had a mean age of 73±6, 41% male, 82% Caucasian. Those 
with greater sST2 concentrations were older and more likely to be male, African-American, and to have traditional CV risk factors and prevalent CAD 
(p<0.01 for all trends). Progressively higher sST2 concentrations were predictive of incident HF and CV death even after adjustment for clinical risk 
factors (Table).
conclusions: sST2 is a newer biomarker that is often increased in older adults. It remains an independent predictor of CV events after adjustment 
for known CV comorbidities.
Event Rate (/100-person-yrs) Hazard Ratio (95% CI)
Incident HF Unadjusted (N=3915) Risk-factor Adjusted (N=3886)
sST2 quintile* (ng/mL)
Q1 (<17.6) 2.1 (1.8, 2.4) Reference Reference
Q2 (17.6-21.47) 2.3 (2.0, 2.6) 1.10 (0.91, 1.33) 0.98 (0.80, 1.19)
Q3 (21.48-25.6) 2.5 (2.2, 2.8) 1.22 (1.02, 1.49) 1.05 (0.87, 1.28)
Q4 (25.61-31.38) 3.2 (2.8, 3.6) 1.60 (1.33, 1.92) 1.19 (0.98, 1.44)
Q5 (>31.38) 3.7 (3.3, 4.2) 1.91 (1.59, 2.29) 1.34 (1.10, 1.63)
ln(sST2) 2.06 (1.75, 2.43) 1.46 (1.22, 1.75)
sST2>35 ng/mL
(N=495, 12.6%) 1.72 (1.47, 2.02) 1.36 (1.15, 1.61)
CV death
Q1 (<17.6) 0.9 (0.7, 1.1) Reference Reference
Q2 (17.6-21.47) 1.0 (0.8, 1.2) 1.06 (0.85, 1.32) 0.96 (0.77, 1.19)
Q3 (21.48-25.6) 1.6 (1.4, 1.9) 1.58 (1.29, 1.94) 1.26 (1.02, 1.55)
Q4 (25.61-31.38) 1.8 (1.6, 2.1) 1.79 (1.46, 2.18) 1.23 (1.00, 1.51)
Q5 (>31.38) 2.3 (2.0, 2.6) 2.20 (1.80, 2.68) 1.40 (1.13, 1.72)
ln(sST2) 2.34 (1.97, 2.78) 1.51 (1.25, 1.83)
sST2>35 ng/mL
(N=495, 12.6%) 1.87 (1.59, 2.20) 1.36 (1.15, 1.61)
*p<.001 for test for trend across quintiles for Incident HF and CV death.
Risk factor-Adjusted: age, gender, race, systolic BP, diastolic BP, anti-hypertensive medications, coronary heart disease, and diabetes.
